| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
DURHAM, NC – November 2, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026. |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
DURHAM, NC – August 5, 2026 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026. |
| 27 Jul 2026 | SCHEDULE 13G |
| 04 Jun 2026 |
Form 4: Bartholdson John A., Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Sutter Martin P, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Stalnecker Susan M, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Nohra Guy P, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Neels Guido J, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: McMurry-Heath Michelle, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Ladone Mary Kay, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Hawkins William A, Director
Received 39,789 shares by exercise or conversion · Granted 30,994 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Cowdy Philip G., Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
Form 4: Beyer Pat, Director
Received 32,282 shares by exercise or conversion · Granted 25,146 Restricted Stock Units |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Bioventus, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 3, 2026. A total of 75,279,174 shares (the “Shares”) of both Class A common stock and Class B common stock (collectively, th... |
| 29 May 2026 | SD |
| 21 May 2026 |
8-K: Regulation FD Disclosure
On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators, including the Company’s Exogen® Ultrasound Bone Healing System, from Class III to Class II devices.... |
Loading...